Sandra Leal (President)Theresa Tolle (President-elect)The American Pharmacists Association (APhA, previously known as the American Pharmaceutical Association), founded in 1852, is the first-established professional society of pharmacists in the United States. The association consists of more than 62,000 practicing pharmacists, pharmaceutical scientists, student pharmacists, pharmacy technicians, and others interested in the profession. Nearly all U.S. pharmacy specialty organizations were originally a section or part of this association. Mary Munson Runge became the first woman and the first African-American elected president of this association in 1979; she was president for two terms, from 1979 to 1981.
AIM The “2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia” retires and replaces the “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol.” METHODS A comprehensive literature search was conducted from October 2024 to December 2024 to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a).
Most diabetes care is delivered in primary care, yet diabetes technologies remain inconsistently integrated. Workforce, training, time, data infrastructure, and insurance barriers contribute to inequitable access and adoption. This scientific statement provides evidence-informed recommendations for integrating diabetes technology into primary care practices. The American Diabetes Association (ADA) convened an interdisciplinary panel that met in person at the Diabetes Technology Meeting in October 2025. Panelists reviewed available evidence, published between 2020 and 2025, on diabetes technology implementation in primary care, with a focus on clear statements and recommendations addressing technology access and adoption, team-based workflows, continuous glucose monitoring, connected insulin delivery, and implementation barriers and opportunities. Virtual meetings were convened over the next 2 months to further develop and finalize statements and recommendations. Together, the ADA and interdisciplinary panel developed 16 consensus statements and 10 key recommendations. Diabetes technologies can be safely and effectively integrated into primary care practices when supported by standardized workflows, appropriate training, defined team roles, and access to specialty expertise. Equitable implementation also requires addressing coverage, affordability, digital literacy, broadband access, interoperability, and workforce development. Integrating diabetes technology into primary care is feasible and necessary to advance equitable, person-centered, data-informed care. Health systems, practices, payors, professional organizations, manufacturers, and policymakers should align resources, training, workflows, payment, and infrastructure to support sustainable implementation and improve outcomes for people with diabetes.
This record preserves the official patient information leaflet for Agnucaston® film-coated tablets, an authorized herbal medicinal product formulated by Bionorica AG (Neumarkt, Germany; Ref: RF 1334202 EG). Clinical Profile & Pharmacological Summary:1. Active Substance & Formulation: Each 125.0 mg film-coated tablet contains 20.00 mg of dry extract derived from the fruit of the chaste tree (Extr. Vitex Agni casti e fruct. spir. sicc. 2:1; tablet core standardized with 16-24% native extract and 84-76% polyvidone). Excipients include povidone, lactose monohydrate, magnesium stearate, macrogol, talc, ammonium methacrylate copolymer, titanium dioxide (E 171), yellow iron oxide (E 172), and indigotine lacquer (E 132).2. Therapeutic Indications: Indicated exclusively for female patients presenting with: - Menstrual disorders (irregularities of cycle duration and flow) - Mastodynia, frequently accompanied by breast pain (mastalgia) - Premenstrual syndrome (PMS)3. Posology and Administration: Unless otherwise directed by a physician, the standard dosage is one film-coated tablet once daily in the morning, swallowed whole. Therapy is uninterrupted and continues throughout menstruation. Efficacy requires chronic administration spanning several months; if symptoms re-emerge post-cessation, medical re-evaluation is warranted.4. Contraindications and Precautions: No general contraindications known to date; strictly contraindicated during pregnancy and throughout lactation.5. Undesirable Effects: Cutaneous allergic reactions occur rarely; severe allergic forms have been documented in isolated instances.6. Interactions: No drug or substance interactions are known to date.7. Storage: Store in a dry environment at room temperature, out of the reach of children. Primary Source: Official Bionorica AG Patient Information Leaflet.
AIM:The "2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia" retires and replaces the "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol." METHODS:A comprehensive literature search was conducted from October 2024 to December 2024 to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE:The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a).
Fifteen years ago, a community pharmacist's role in the United States was dispensing medication. Five years ago, it expanded to include administering routine vaccines. Fifteen years from now, the authors posit that it will include minor acute illness evaluation and treatment, chronic disease prevention, and complex disease management, including medication prescribing and administration. This evolution, which just began recently in the United States but is well under way in many other countries, would help to relieve pressure on primary care, control costs, improve outcomes, and increase access to essential services, particularly in rural communities. It will require policy reforms and investments in key enablers, including workforce development, integration and interoperability with the rest of the health ecosystem, and systems and structures to ensure safe, high-quality care. Ultimately, this expansion of the role of the community pharmacist will align care more closely with locations that are convenient to patients and leverage relationships already imbued with trust. The authors describe the structural changes needed to accomplish this transformation.